Clinical trial · Observational
Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer
Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program Entitled START-HPV (STudy of Primary Screening in the ARdennes Department by Testing for HPV Infection)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical cancer is due to a persistent infection with a group of viruses known as high-risk Human Papillomaviruses (hrHPV). Viral DNA can be easily detected in a cervical sample by a procedure called 'HPV testing', which can be used as a relevant screening test. A pilot screening program called START-HPV has been set up in the Ardennes, a French administrative area localized in the North of France, with HPV testing as a primary screening test.This observational study aimed to evaluate hrHPV genotypes repartition in the population who participate in the START-HPV screening program. This study will allow a better knowledge of hrHPV infection epidemiology in a screened population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human papillomavirus genotyping | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- women tested positive for hrHPV
- description
- All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
- interventionNames
- Biological: Human papillomavirus genotyping
Primary outcomes (1)
- measure
- HPV genotyping
- timeFrame
- Day 0
- description
- DNA extraction from cervical smears (DNAPap Cervical Sampler device, Qiagen) or from self-collected vaginal lavages (Delphi-screener device, DelphiBioscience) and HPV genotyping with the Multiplex HPV Genotyping kit© (Multimetrix, Progen) based on a Luminex technology
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 31 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * to live in the Ardennes department (France) * affiliation to a health insurance organism * 31 to 65 years old Exclusion Criteria: * current follow-up for cervical cytological abnormalities * history of hysterectomy * reimbursement for a Pap smear in the last 3 years
References
Publications (0)
Data not yet available